Inhaled Nitric Oxide (iNO)
Inhaled Nitric Oxide (iNO) is a pharmaceutical drug with 8 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
6
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
1
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Inhaled Nitric Oxide for Prevention of Postoperative AKI in High-Risk Cardiac Surgery Patients
Effect of iNO in Patients With Submassive and Massive PE
Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)
Clinical Trials (8)
Inhaled Nitric Oxide for Prevention of Postoperative AKI in High-Risk Cardiac Surgery Patients
Effect of iNO in Patients With Submassive and Massive PE
Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)
The Effects of Inhaled Nitric Oxide After Fontan Operation
iNOPulse for COVID-19
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8